Prescott Woodruff, MD, MPH
Profile
Research program includes clinical and basic science approaches to study the effects of cigarette smoke on lung inflammation. He is also the Principal Investigator on the NIH-funded Spiromics Project and a Co-investigator on the COPD Clinical Research Network. Dr. Woodruff received his B.A, from Wesleyan University in 1989, received his M.D. degree from the Columbia College of Physicians and Surgeons in 1993, and completed Internal Medicine residency training at the Massachusetts General Hospital. After residency training, he obtained research training as a Research Fellow in the Channing Laboratory, Division of Respiratory Epidemiology, at the Brigham and Women’s Hospital, and pursued graduate studies leading to a Masters in Public Health from the Harvard School of Public Health in 1998. He undertook fellowship training in Pulmonary and Critical Care Medicine here at UCSF beginning in 1998 and joined the UCSF faculty in 2002. He is currently an Assistant Professor of Medicine in the Department of Medicine and is an investigator in the Airway Clinical Research Center as well as the General Clinical Research Center. Please refer to my website for more information: http://woodrufflab.ucsf.edu/
Wesleyan University, B.A., 1989, Letters
Columbia College of Physicians & Surgeons, NY, 1993, Medicine
Massachusetts General Hospital, Resident, 1993-1996, Internal Medicine
Harvard School of Public Health, M.P.H., 1998, Epidemiology
Brigham and Women’s Hospital, Fellow, 1997-1998, Respiratory Epidemiology
University of California, San Francisco, Fellow, 1998-2002, Pulmonary/Critical Care Medicine
1. Woodruff PG*, Koth LL*, Yang YH, Rodriguez MW, Favoreto S, Dolganov GM, Paquet AC, Erle DJ. A distinctive alveolar macrophage activation state induced by cigarette smoking. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1383-92. PMCID: PMC2718436
2. Innes AL*, Woodruff PG*, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest. 2006 Oct;130(4):1102-8.
3. Schane RE, Walter LC, Dinno A, Covinsky KE, Woodruff PG. Prevalence and risk factors for depressive symptoms in persons with chronic obstructive pulmonary disease. J Gen Intern Med. 2008 Nov;23(11):1757-62. Epub 2008 Aug 9. Erratum in: J Gen Intern Med. 2008 Nov;23(11):1930.
4. Seibold MA, Donnelly S, Solon M, Innes A, Woodruff PG, Boot RG, Burchard EG, Fahy JV. Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. J Allergy Clin Immunol. 2008 Nov;122(5):944-950. PMCID: PMC2666777
5. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon PD, Woodruff PG, Washko GR, Connett JE, Anthonisen NR, Bailey WC; COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Sep 15;180(6):499-505. Epub 2009 Jun 25.
6. Woodruff PG, Wolff M, Hohlfeld JM, Krug N, Dransfield MT, Sutherland ER, Criner GJ, Kim V, Prasse A, Nivens MC, Tetzlaff K, Heilker R, Fahy JV. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Mar 1;181(5):438-45. Epub 2009 Dec 10.
7. Koth LL, Cambier CJ, Ellwanger A, Solon M, Hou L, Lanier LL, Abram CL, Hamerman JA, Woodruff PG. DAP12 is required for macrophage recruitment to the lung in response to cigarette smoke and chemotaxis toward CCL2. J Immunol. 2010 Jun 1;184(11):6522-8. Epub 2010 Apr 26.